Clínica Médica

Um estudo de caso-controle mostrou risco aumentado de miocardite após vacinação contra COVID-19 com vacina mRNA em comparação com vacina de vírus inativado.

25 Jan, 2022 | 15:04h

Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case–Control Study – Annals of Internal Medicine

Comunicado de imprensa: BNT162b2 COVID-19 vaccine associated with increased risk of carditis – American College of Physicians

Conteúdos relacionados:

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

---

Avaliação inicial da gravidade clínica da variante Ômicron do SARS-CoV-2 na África do Sul.

25 Jan, 2022 | 15:02h

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study – The Lancet

Comentário: Omicron severity: milder but not mild – The Lancet

 

Comentário no Twitter

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in S. Africa, Lancet. Individuals with Omicron vs previous infections 80% lower odds of being admitted to hospital, 70% lower odds of severe disease than Deltahttps://t.co/528NWfKrDN

— Monica Gandhi MD, MPH (@MonicaGandhi9) January 23, 2022

 

---

[Preprint] Estudo de coorte | Risco reduzido de internação associado com infecção pela variante Ômicron do SARS-CoV-2 em relação à variante Delta.

25 Jan, 2022 | 15:01h

Reduced Risk of Hospitalisation Associated With Infection With SARS-CoV-2 Omicron Relative to Delta: A Danish Cohort Study – SSRN / Preprints with The Lancet

Comentários:

Danish report: lower risk of hospitalisation with Omicron – Copenhagen Post

Omicron has a 36% lower risk for hospitalization compared to Delta: Denmark study – Outbreak News Today

 

Comentário no Twitter

New Danish population-based cohort study confirms lower (36%, 95%CI 44%-25%) risk of hospitalization with Omicron compared with Delta.
The risk also seems to be reduced irrespective of vaccination status.

Pre-print can be found here: https://t.co/LfRrw1H3CY pic.twitter.com/Ql3zPyZyRE

— Anders Husby (@a_husby) January 20, 2022

 

---

[Preprint] A variante Ômicron do SARS-CoV-2 está associada com risco reduzido de internação e permanência em hospital, em comparação com a variante Delta.

25 Jan, 2022 | 14:59h

Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2) – medRxiv

 

Comentário no Twitter

In Portugal, Omicron hospitalizations were 75% reduced compared with Delta, risk adjusted. Vaccination reduced hospitalizations 84%, w/a booster 93%https://t.co/MvkfuF3mzx pic.twitter.com/zyk2INWNis

— Eric Topol (@EricTopol) January 23, 2022

 

---

Revisão JACC de estado da arte | Diagnóstico e avaliação da cardiomiopatia hipertrófica.

25 Jan, 2022 | 14:51h

Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review – Journal of the American College of Cardiology

---

Revisão JACC de estado da arte | Tratamento da cardiomiopatia hipertrófica.

25 Jan, 2022 | 14:50h

Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review – Journal of the American College of Cardiology

---

Revisão | Diagnóstico e tratamento do distúrbio neurológico funcional.

25 Jan, 2022 | 14:49h

Diagnosis and management of functional neurological disorder – The BMJ

---

Estudo randomizado | Ertapenem 1.000 mg em dose única é não inferior a ceftriaxona 500 mg em dose única para o tratamento da gonorreia.

25 Jan, 2022 | 14:48h

Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial – The Lancet Infectious Diseases (link para o resumo – $ para o texto completo)

 

Comentário no Twitter (fio – clique para saber mais)

New from @TheLancetInfDis Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial by @henryjdevries and colleagues https://t.co/K2fw5ORNlm pic.twitter.com/d8wz1Vc41Q

— The Lancet HIV (@TheLancetHIV) January 24, 2022

 

---

Podcast | Dicas sobre disfunção erétil.

25 Jan, 2022 | 14:44h

#317 Erectile Dysfunction – The Curbsiders

---

Estudo de coorte | Em pacientes com prótese articular, a antibioticoprofilaxia provavelmente não é necessária para procedimentos dentais invasivos.

25 Jan, 2022 | 14:39h

Analysis of Prosthetic Joint Infections Following Invasive Dental Procedures in England – JAMA Network Open

Comentário: Prophylactic Antibiotics Not Needed Before Invasive Dental Procedures – HealthDay

 

Comentário no Twitter

Case-crossover study analyzing the incidence of invasive dental procedures (IDP) over the 15-months before 9,427 late prosthetic joint infection hospital admissions (LPJI) and found no evidence of a temporal association b/w IDP and LPJI. https://t.co/hcpwpN0B4H

— JAMA Network Open (@JAMANetworkOpen) January 19, 2022

 

---